King's Research Portal

Associations of neuropsychiatric symptoms and antidepressant prescription with survival in Alzheimer's disease

(Author's accepted manuscript; published article: https://doi.org/10.1016/j.jamda.2017.07.001)

Christoph Mueller MD [a,b], Jonathan Huntley PhD [a,b], Brendon Stubbs PhD [a,b], Andrew Sommerlad MSc [c,d], Andre F Carvalho MD [e], Gayan Perera PhD [a], Robert Stewart MD [a,b], Nicola Veronese MD [f,g]

[a] King's College London, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), London, United Kingdom.

[b] South London and Maudsley NHS Foundation Trust, Denmark Hill, London, United Kingdom.

[c] Division of Psychiatry, University College London, London, United Kingdom

[d] Camden and Islington NHS Foundation Trust, London

[e] Federal University of Ceará, Faculty of Medicine, Department of Clinical Medicine, Translational Psychiatry Research Group, Fortaleza, CE, Brazil.

[f] National Research Council, Neuroscience Institute, Aging Branch, Padua, Italy.

[g] Institute for Clinical Research and Education in Medicine, IREM, Padua, Italy.

Corresponding author: Christoph Mueller, MD; King's College London, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), De Crespigny Park, London Box SE5 8AF, United Kingdom; email: christoph.mueller@kcl.ac.uk; phone: 020 7848 0626

Abstract

Objective: Depression is associated with increased mortality in community samples. The use of antidepressant medication may also increase mortality, however, it is still unclear whether taking antidepressants before or after a diagnosis of dementia influences survival.

Design: Retrospective.

Setting: A cohort with a diagnosis of Alzheimer's disease (AD) from a large mental health and dementia care database in South London, linked to hospitalization and mortality data

Participants: Mild dementia (mini-mental state examination ≥18/30) at the point of diagnosis.

Measurements: We ascertained antidepressant prescription, either in the 6 months before or after dementia diagnosis, and used the HoNOS65+, a standard clinician-rated measure of patient wellbeing, to determine depression severity and other neuropsychiatric, physical health and functional difficulties. We conducted a survival analysis, adjusted for potential confounders and addressed possible confounding by indication through adjusting for a propensity score.

Results: Of 5,473 patients with AD, 22.8% were prescribed an antidepressant in a one-year window around dementia diagnosis. Of these 2415 (44.1%) died in the follow-up period (mean (SD) 3.5 (2.4) years). Prescription of an antidepressant, both before and after dementia diagnosis, was significantly associated with higher mortality after adjusting for a broad range of potential confounders including symptom severity, functional status and physical illness (hazard ratio 1.22; 95% CI 1.08-1.37 for prescription prior to dementia diagnosis; 95% CI 1.04-1.45 for prescription post dementia diagnosis). In stratified analyses risks remained significant in those without neuropsychiatric symptoms.

Conclusion: The prescription of antidepressants around the time of dementia diagnosis may be a risk factor for mortality.

Introduction

There is increasing recognition that psychiatric comorbidities are a common and distressing feature among people with Alzheimer's disease (AD), [1] of which depression is one of the most prevalent and troubling. [2] Previous meta-analyses have concluded that depression is associated with increased risk of a person developing AD, potentially due to inflammatory processes, stress or reduced cognitive reserve.[3] Furthermore, the prevalence of depression among people with AD may be as high as 80%[4,5], and probably associated with higher mortality[6], greater medical comorbidity and poorer quality of life for the individual and careers [7].

Antidepressant medications are a commonly used treatment for depression in the general population [8] and are also used in people with AD, [9] although there is uncertainty as to the benefits in people affected by dementia and/or AD. Some trials support a beneficial effect [10-12] but more recent studies report that antidepressants are not effective [13,14] as indicated by a Cochrane review.[15]

In addition, there is a contentious debate about the potential association between antidepressant medication and higher mortality among people with AD. In the general population, there have been mixed results for this association, including lower mortality [16], no association [17] and higher mortality.[18] However, information on people with AD remains sparse. One previous study among people with dementia, found that antidepressant medication was associated with a significantly higher mortality risk of 36%,[19] but another study found 18% lower mortality in people taking antidepressant medications for 3 years before an AD diagnosis.[20]

Given the high comorbidity of depression among people with AD, the common use of antidepressants, but paucity of studies on the relationship with mortality in this population, we aimed to investigate the association between the use of antidepressants and mortality in a large cohort of people with diagnosed AD.

Methods

Data Source and Setting

We obtained the data for this study using the South London and Maudsley NHS Foundation

Trust (SLaM) Clinical Record Interactive Search (CRIS) application. CRIS has ethical approval

(Oxford Research Ethics Committee C, reference 08/H0606/71+5) as an anonymised data source

and, within a robust governance framework, it provides research access to anonymised copies of

SLaM's electronic health records.[21,22] SLaM is one of Europe's largest providers for dementia

and mental health care and serves a geographic catchment of four South London boroughs

(Lambeth, Lewisham, Southwark, and Croydon) with a population of over 1.2 million residents.

Its electronic health records contain data on more than 270,000 cases across all age groups and

mental health services, and secure linkages have been made to national data on hospitalisations

(Hospital Episode Statistics; HES) and mortality. Data are extracted from routinely completed

compulsory fields and supplemented by a range of natural language processing algorithms using

General Architecture for Text Engineering (GATE) software to interrogate free text clinical

records and correspondence.[21,23]

Participants

We used CRIS to identify patients who received a first diagnosis of dementia according to

International Classification of Diseases, Tenth Revision (ICD-10) codes[24] from SLaM outpatient

services within between 1st January 2006 and 28th July 2016. To be included, patients needed to

have a diagnosis of Alzheimer's disease (etiher at first diagnosis or during the follow-up period),

and diagnosed with dementia in the mild stage defined as an Mini Mental State Examination (MMSE) score of 18 or higher at that time [25].

Variables

To distinguish longstanding antidepressant use from use associated with the diagnosis of dementia we defined two exposure groups. Patients were classified as prescribed antidepressants prior to dementia diagnosis if any antidepressant was mentioned in their case record in the 6 months prior to dementia diagnosis. If the the antidepressant was continued after dementia diagnosis patients were also classified in this group. The second exposure group consisted of those prescribed an antidepressant in the 6 months after dementia diagnosis. Patients with AD who were not prescribed an antidepressant in the one-year window around dementia diagnosis served as control group.

Baseline covariates recorded were age, gender, ethnicity, marital status, a neighbourhood-level index of multiple deprivation[26], and MMSE score closest to dementia diagnosis. To account for cerebrovascular co-morbidity we ascertained if an ICD-10 diagnosis of vascular (F01) or mixed-type Alzheimer's disease (F00.2) was mentioned in the follow-up period. General physical health and multi-morbidty was described through the 'Physical illness and disability problems' subscale of the Nation Outcome Scales (HoNOS65+) instrument. The HoNOS65+ is a standard measure of patient wellbeing used in UK mental health and dementia services and subscales are each rated 0 (no problem) to 4 (severe or very severe problem).[27,28] In addition to the physical illness subscale, we also ascertained subscales relating to mental health symptoms and functional abilities. To facilitate interpretation, we dichotomised these to 'minor or no problem' (scores of 0

and 1) and 'mild to severe problems' (scores 2 to 4). Further, HoNOS65+ mental health problem scores were used to define subgroups of patients according to their neuropsychiatric symptom profile.

Statistical analysis

Analyses were conducted using STATA 13 software. Patients prescribed antidepressants were compared to the remainder with respect to other covariates. Patients were followed-up until their death or a census date on 10th December 2016. We used log-rank tests to compare survival between exposure groups and then applied Cox regression models to investigate associations between antidepressant prescription and survival. In order to reduce impact of confounding by indication, propensity scores were calculated. [29] These represent the probability of being treated with an antidepressant based on a regression model which included all the above mentioned covariates and we included the propensity score in a Cox model.

Results

Population characteristics

Among the 10,011 patients diagnosed with AD initially identified, of which 8,695 had an MMSE score recorded at diagnosis. 5,473 patients fulfilled inclusion criteria. Of these, 2415 (44.1%) died in the follow-up period and mean (SD) follow-up time to death or the end of the observation period was 3.5 (2.4) years. 901 (16.5%) patients were prescribed an antidepressant prior to dementia diagnosis, of which 472 (8.6%) remained on the medication after diagnosis. 347 (6.3%) patients were prescribed an antidepressant after dementia diagnosis.

Characteristics of antidepressant non-receivers and the two exposure groups are compared in Table 1. Antidepressant receivers were younger, more likely to be female, from a White ethnic background, and from more deprived areas. Those receiving antidepressants after dementia diagnosis had lower cognitive scores than those without or prior antidepressant prescription. Further patients prescribed antidepressants had worse scores on HONOS65+ subscales for agitated behaviour, non-accidental self injury, hallucinations or delusions, depressed mood, physical illness, and functional scales (activities of daily living, occupation and activities, social relationships). No signifcant difference in cerebrovascular co-morbidty was detected between groups.

Predictors of mortality

Adjusted and unadjusted multivariate Cox regression models are presented in Table 2. In models adjusted for demographics and cognition the following factors were assciated with higher mortality in the study cohort: higher age, being male, White ethnicity background, being from

more deprived areas and having a lower MMSE. In addition, poorer physical health and functional status, as well as the following neuropsychiatric symptoms were associated whith increased mortality:agitated behaviour, hallucinations or delusions, and depressed mood. Of note, two factors associated with antidepressant prescribing (lower age and female gender) were linked to better survival.

Antidepressant receipt and survival

A log rank test demonstrated significant differences in survival function between antidepressant non-receivers and those prescribed antidepressants before or after dementia diagnosis (chi^2=14.0, p<0.01). Cox regression models also showed significant associations between antidepressant prescription and an increased risk for all-cause mortality. Associations did not seem to differ significantly between those prescribed antidepressant prior and after dementia diagnosis and remained significant after including a broad range of confounders into the models (Table 3). We created standard propensity scores from all available variables and included those as covariates in a Cox regression model. In propensity score adjusted models both exposure groups differed in 95% confidence intervals, but equal hazard ratios of 1.22 compared to non-rescription were detected.

Stratified analyses according to neuropsychiatric symptom profiles

We assessed the effect of antidepressant prescription in patients with depressed mood (n=483), with depressed mood and other co-morbid neuropsychiatric symptoms (agitated behaviour and/or psychotic symptoms; n=170), with agitation and/or psychosis, but no depressive symptoms (n=653), and in patients without any of the aforementioned neuropsychiatric problems (n=3,975)

(see Table 4). In patients with depressed mood antidepressant prescription prior to, but not after dementia diagnosis, was significantly associated with an increased mortality risk. In patients with agitated behaviour and/or psychotic symptoms antidepressant prescription did not lead to a significantly increased risk of death. Only in the group suffering from depressed mood and co-morbid agitation/psychosis a trend towards increased mortality was detected in those prescribed an antidepressant after dementia diagnosis in a fully adjusted Cox regression model (HR 1.91; 95% CI 0.89-4.11; p=0.08). Most notably, in the group without depression, agitation or psychosis, both antidepressant prescription prior and after dementia diagnosis resulted in an increased hazard for all-cause mortality.

Differences in survival times

In those who died in the follow-up period (n=2,415), mean (SD) survival time from dementia diagnosis to death was 3.3 (2.3) years. Mean (SD) survival time for patients not prescribed antidepressants was 3.4 (2.3) years, and for patients taking antidepressants prior to dementia diagnosis 3.1 (2.1) years and post dementia diagnosis 3.0 (2.3) years (p=0.01). This indicates a mean difference of 3-4 months of survival between antidepressant receivers and non-receivers. Survival time was significantly (p<0.01) shorter for patients with depressive symptoms (2.9 (SD 2.3) years) than those presenting without depressed mood (3.4 (SD 2.3) years). In those who suffered from depressed mode and died in the follow-up period (n=266), no significant differences in survival time were detected between antidepressant receivers and non-receivers (p=0.77).

Discussion

In this study of 5,473 patients with clinically diagnosed AD, we found that people who took antidepressant medications in the year encompassing the dementia diagnosis were more likely to die during the follow up period. This association was similar in those with pre-dementia antidepressant prescritption and those receiving the medication after dementia diagnosis and remained robust after adjustment for potential confounders and in analyses including a propensity score representing the risk of being treated. Moreover, the presence of neuropsychiatric, functional, and physical health problems and socio-economic deprivation were associated with a higher mortality risk in this cohort of AD patients.

Approximately 23% of the sample with AD were prescibed at least one antidepressant medication, and almost three quarters of those already before dementia diagnosis. Compared to those not taking antidepressants, participants taking such medication had a higher presence of neuropsychiatric symptoms, had worse functioning according to HONOS65+ scores and worse physical health. Altogether, these findings suggest that participants taking antidepressant medications had a higher presence of risk factors for mortality, which may partly explain our findings. However, the association of interest remained robust, although relatively small, after adjustment for these confounders.

There are a number of potential mechanisms by which antidepressant medication may influence mortality in people with AD. First, antidepressant medications are associated with a higher risk of several medical conditions also associated with higher mortality risk; these include falls [19,30,31], poor bone health [32], fractures [33], and potentially cardiovascular disease [34]. Second,

12

antidpressants may interact with other medications taken by people affected by AD and increase the likelihood of adverse effects. For example, the use of some antidepressants could lead to a prolongation of QT intervals, especially if co-prescribed with other medications commonly used in people affected by AD, such as antipsychotics. [35] Finally, some antidepressants (like tricyclic medications) may have a role on on basal heart rate and heart rate variability[36], two important factors for mortality.[37]

Previous literature considering the relationship between antidepressant use and mortality among people with AD is equivocal and our findings add to a growing picture of a complex relationship. A large study including 20,050 participants affected by various types of dementia [20] reported that the use of antidepressant medications is associated with a significant lower risk of mortality. However, other large studies have reported an association with increased mortality. [19] Several reasons could explain these conflicting findings in the literature and our own data. First, factors as cognitive function, diagnostic criteria for AD, and the presence of diseases at higher risk of mortality could explain the differences. Second, the authors of the first study found that only a prolonged use of antidepressants (more than 3 years) was associated with a lower risk of mortality, whilst using antidepressants at the time of diagnosis or less than 3 years was not associated with any decreased risk. [20] Finally, our study had a considerably longer follow-up time than Enache et al. [20], who only observed their patients for two years after dementia diagnosis. It is conceivable that the hazardous effects of antidepressants only become apparent later in the dementia disease course.

The findings of our study should be interpreted within its limitations. First, it is an observational study and so we cannot exclude that some potential confounders not considered in our analysis

could play a role in the association between antidepressants and mortality. Second, we did not have any information regarding the causes of mortality.Third, the type of antidepressant was not ascertained and so we are not able to conclude if a particular medication or class is responsible for the increased mortality found. Fourth, we assessed the use of antidepressants only in a window ranging from six months before to six months after first dementia diagnosis and this could introduce a bias in our results. Depressive symptoms, such as social withdrawal can be a prodromal feature of AD, [38] rather than representing clinical depression and we are unable to deliniate the clinical phenotype of our study sample. Fifth, we did not have sufficient information to adjust for level of education, although this is a factor partly reflected in the index of neighbourhood-level socio-economic status and a prospective studies have not found any association between educational level and survival in AD[39]. Sixth, co-morbidity was primarily ascertained through the HoNOS65+ 'Physical illness and disability problems' subscale, which although being widely used as routine measure of clinical outcome in dementia services in the UK, is a relatively brief measure.

Conclusion

Our findings suggest that antidepressants should be used cautiously in older people affected by AD, consistent with a longitudinal study showing that antidepressants are associated with a higher risk of adverse outcomes, including falls, hyponatraemia, cardiovascular and cerebrovascular conditions. [40] Since the benefits of antidepressant medications on mood in dementia may be limited, the prescribing clinician should carefully consider the risks and

benefits of doing so. As this is a retrospective observational study, more solid evidence could be achieved through replicating these results in a prospective cohort study or a randomized controlled trial and future studies are needed to better elucidate the true role of antidepressants in AD.

Conflict of interest

RS has received research funding from Roche, Pfizer, Janssen, Lundbeck and In-Silico-Bioscience outside the submitted work. None of the authors have any financial arrangements, organizational affiliations or other relationships that might give rise to any conflict of interest regarding the subject matter of the manuscript submitted.

References:

1.   Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association.* 2011;7(5):532-539.
2.   Modrego PJ. Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment. *Journal of Alzheimer's disease : JAD.* 2010;21(4):1077-1087.
3.   Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. *Archives of general psychiatry.* 2006;63(5):530-538.
4.   Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. *Dementia and geriatric cognitive disorders.* 2004;17(1-2):55-64.
5.   Chi S, Wang C, Jiang T, Zhu XC, Yu JT, Tan L. The prevalence of depression in Alzheimer's disease: a systematic review and meta-analysis. *Current Alzheimer research.* 2015;12(2):189-198.
6.   Lara E, Haro JM, Tang MX, Manly J, Stern Y. Exploring the excess mortality due to depressive symptoms in a community-based sample: The role of Alzheimer's Disease. *J Affect Disord.* 2016;202:163-170.
7.   Gomez-Gallego M, Gomez-Garcia J, Ato-Lozano E. The mediating role of depression in the association between disability and quality of life in Alzheimer's disease. *Aging & mental health.* 2017;21(2):163-172.
8.   Taylor WD. Depression in the Elderly. *New England Journal of Medicine.* 2014;371(13):1228-1236.
9.   Zhu CW, Livote EE, Kahle-Wrobleski K, et al. Utilization of antihypertensives, antidepressants, antipsychotics, and hormones in Alzheimer disease. *Alzheimer disease and associated disorders.* 2011;25(2):144-148.
10.   Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. *The Journal of neuropsychiatry and clinical neurosciences.* 1996;8(3):270-275.
11.   Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. *The British journal of psychiatry : the journal of mental science.* 1990;157:894-901.
12.   Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. *Archives of general psychiatry.* 2003;60(7):737-746.
13.   de Vasconcelos Cunha UG, Lopes Rocha F, Avila de Melo R, et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. *Dementia and geriatric cognitive disorders.* 2007;24(1):36-41.
14.   Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. *International psychogeriatrics.* 2001;13(2):233-240.
15.   Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. *The Cochrane database of systematic reviews.* 2002(4):CD003944.
16.   Krivoy A, Balicer RD, Feldman B, et al. Adherence to antidepressant therapy and mortality rates in ischaemic heart disease: cohort study. *The British journal of psychiatry : the journal of mental science.* 2015;206(4):297-301.
17.   Zivin K, Kim HM, Yosef M, et al. Antidepressant Medication Treatment and Risk of Death. *Journal of clinical psychopharmacology.* 2016;36(5):445-452.
18.   Hansen RA, Khodneva Y, Glasser SP, Qian J, Redmond N, Safford MM. Antidepressant Medication Use and Its Association With Cardiovascular Disease and All-Cause Mortality in the

Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *The Annals of pharmacotherapy.* 2016;50(4):253-261.

19.   Jennum P, Baandrup L, Ibsen R, Kjellberg J. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.* 2015;25(11):1906-1913.

20.   Enache D, Fereshtehnejad SM, Kareholt I, et al. Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. *Acta psychiatrica Scandinavica.* 2016;134(5):430-440.

21.   Perera G, Broadbent M, Callard F, et al. Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource. *BMJ open.* 2016;6(3):e008721.

22.   Fernandes AC, Cloete D, Broadbent MT, et al. Development and evaluation of a de-identification procedure for a case register sourced from mental health electronic records. *BMC medical informatics and decision making.* 2013;13:71.

23.   Cunningham H, Wilks Y, Gaizauskas RJ. Gate: a general architecture for text engineering. Paper presented at: Proceedings of the 16th conference on Computational linguistics-Volume 21996.

24.   Organization WH. International statistical classification of diseases and related health problems. 2009.

25.   Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* 1975;12(3):189-198.

26.   Noble M, McLennan D, Wilkinson K, et al. The English indices of deprivation 2007. 2007.

27.   Burns A, Beevor A, Lelliott P, et al. Health of the Nation Outcome Scales for elderly people (HoNOS 65+). *Br J Psychiatry.* 1999;174:424-427.

28.   Pirkis JE, Burgess PM, Kirk PK, Dodson S, Coombs TJ, Williamson MK. A review of the psychometric properties of the Health of the Nation Outcome Scales (HoNOS) family of measures. *Health Qual Life Outcomes.* 2005;3:76.

29.   Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behavioral Research.* 2011;46(3):399-424.

30.   Martinez-Ramirez D, Giugni JC, Almeida L, et al. Association between antidepressants and falls in Parkinson's disease. *Journal of neurology.* 2016;263(1):76-82.

31.   Stubbs B, Stubbs J, Gnanaraj SD, Soundy A. Falls in older adults with major depressive disorder (MDD): a systematic review and exploratory meta-analysis of prospective studies. *International psychogeriatrics.* 2016;28(1):23-29.

32.   Stubbs B, Brefka S, Dallmeier D, Stubbs J, Vancampfort D, Denkinger MD. Depression and Reduced Bone Mineral Density at the Hip and Lumbar Spine: A Comparative Meta-Analysis of Studies in Adults 60 Years and Older. *Psychosomatic medicine.* 2016;78(4):492-500.

33.   Rabenda V, Nicolet D, Beaudart C, Bruyere O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.* 2013;24(1):121-137.

34.   Nezafati MH, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: A narrative review. *ARYA atherosclerosis.* 2015;11(5):295-304.

35.   Heist EK, Ruskin JN. Drug-Induced Arrhythmia. *Circulation.* 2010;122(14):1426-1435.

36.   Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. *Biological psychiatry.* 2010;67(11):1067-1074.

37.   Zhang GQ, Zhang W. Heart rate, lifespan, and mortality risk. *Ageing research reviews.* 2009;8(1):52-60.

38.   Masters MC, Morris JC, Roe CM. "Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis. *Neurology.* 2015;84(6):617-622.

39.   Rountree SD, Chan W, Pavlik VN, Darby EJ, Doody RS. Factors that influence survival in a probable Alzheimer disease cohort. *Alzheimer's research & therapy.* 2012;4(3):16.

40.   Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. *Bmj.* 2011;343.

Tables & Figures

Table 1: Socio-demographic and clinical characteristics of the sample, by antidepressant status

Risk factors	Antidepressant non-receipt (n=4,225)	Antidepressant receipt prior (and post) dementia diagnosis (n=901)	Antidepressant receipt post dementia diagnosis (n=347)	P value*
Socio-demographic status and cognitive function[†]				
Mean age at dementia diagnosis (SD)	81.3 (7.3)	79.9 (8.7)	80.8 (8.4)	<0.01
Female gender (%)	62.0%	71.1%	70.3%	<0.01
Non-White ethnicity (%)	22.0%	19.1%	17.2%	0.03
Married or cohabiting status (%)	38.0%	34.9%	33.4%	0.08
Mean index of deprivation (SD)	25.2 (11.3)	26.7 (10.8)	26.4 (11.1)	<0.01
Mean MMSE score at diagnosis (SD)	22.8 (3.2)	23.0 (3.3)	22.3 (3.1)	<0.01
HoNOS65+ problem due to mental health symptoms (% with subscale scores 2-4)[†]				
Agitated behaviour	7.7%	16.2%	20.1%	<0.01
Non-accidental self-injury	0.6%	3.4%	2.1%	<0.01
Problem-drinking or drug taking	2.8%	2.6%	2.1%	0.84
Hallucinations or delusions	7.7%	12.3%	13.0%	<0.01
Depressed mood	6.7%	33.6%	26.3%	<0.01
HoNOS65+ functional problem (% with subscale scores 2-4)[†]				
Activities of daily living	40.5%	49.4%	48.1%	<0.01
Living conditions	8.2%	7.5%	10.2%	0.37
Occupational and recreational activities	21.6%	30.8%	32.1%	<0.01
Social relationships	9.2%	17.7%	19.8%	<0.01
HoNOS65+ 'Physical illness or disability problems' scale[†]				<0.01
0-1 (no or minor problem)	62.9%%	51.6%	52.2%	
2 (mild problem)	22.9%%	26.4%	26.3%	
3 (moderately severe problem)	12.4%	18.2%	18.0%	
4 (severe to very severe problem)	1.8%	3.8%	3.5%	
Cerebrovascular co-morbidity	35.1%	35.6%	39.5%	0.26

Notes: * ANOVA, Kruskall-Wallis rank tesk or chi[2] test ; [†] at the time of AD diagnosis

Table 2: Unadjusted and adjusted analyses of associations between covariates and mortality after Alzheimer's disease diagnosis

Covariate status at/around diagnosis	Association with mortality – hazard ratio (95% CI)	
	Unadjusted	Adjusted for demographics[$] & MMSE
Age (per year increment) [†]	**1.08 (1.08-1.09)***	**1.08 (1.08-1.09)***
Female gender	**0.82 (0.76-0.89)***	**0.69 (0.64-0.75)***
Non-white ethnicity	**0.52 (0.45-0.58)***	**0.61 (0.53-0.69)***
Married or cohabiting status[†]	**0.85 (0.78-0.93)***	0.97 (0.88-1.06)
Deprivation score above sample mean[†]	**1.09 (1.01-1.18)***	**1.18 (1.08-1.28)***
MMSE score (per unit increment) [†]	**0.94 (0.93-0.95)***	**0.95 (0.94-0.97)***
HoNOS65+ problem due to mental health symptom [†]		
Agitated behaviour	**1.31 (1.16-1.49)***	**1.30 (1.14-1.47)***
Non-accidental self-injury	1.08 (0.76-1.53)	1.12 (0.79-1.60)
Problem-drinking or drug taking	1.03 (0.80-1.32)	1.21 (0.94-1.57)
Hallucinations or delusions	**1.32 (1.16-1.50)***	**1.33 (1.16-1.52)***
Depressed mood	1.01 (0.89-1.14)	**1.17 (1.03-1.34)***
HoNOS65+ functional problem [†]		
Activities of daily living (ADLs)	**1.73 (1.60-1.88)***	**1.49 (1.37-1.63)***
Living conditions	**1.61 (1.41-1.85)***	**1.51 (1.31-1.74)***
Occupational and recreational activities	**1.42 (1.30-1.56)***	**1.30 (1.18-1.43)***
Social relationships	**1.14 (1.02-1.29)***	**1.17 (1.03-1.32)***
HoNOS65+ 'Physical illness or disability problem'[†]	**1.76 (1.62-1.91)***	**1.57 (1.44-1.71)***
Cerebrovascular co-morbidity	1.07 (0.97-1.19)	1.08 (1.00-1.18)

[†] at the time of AD diagnosis

[$] includes age, gender, ethnicity, marital status, deprivation score at dementia diagnosis

* $p < 0.05$

Table 3: Multivariate Cox regression analyses of association between receiving antidepressant treatment and mortality

Multivariate Cox regression models	Antidepressant receipt prior (and post) dementia diagnosis	Antidepressant receipt dementia diagnosis only
	Hazard ratio (95% CI)	**Hazard ratio (95% CI)**
Unadjusted	**1.15 (1.04-1.29)***	**1.26 (1.08-1.46)***
Adjusted for demographics[$] and cognitive scores	**1.29 (1.16-1.44)***	**1.32 (1.13-1.55)***
Adjusted for demographics, cognitive scores and all mental health and functional problems HoNOS65+ subscales	**1.24 (1.10-1.39)***	**1.28 (1.09-1.51)***
Adjusted for demographics, cognitive scores and hospitalization, HoNOS65+ physical illness subscale, and vascular co-morbidity	**1.22 (1.09-1.36)***	**1.26 (1.08-1.48)***
Fully adjusted (for demographics, cognitive scores, and all HoNOS65+ subscales, and vascular co-morbidity)	**1.20 (1.06-1.35)***	**1.25 (1.06-1.48)***
Adjusted using propensity score as co-variate	**1.22 (1.08-1.37)***	**1.22 (1.04-1.45)***

[$] includes age, gender, ethinicity, marital status, deprivation score at dementia diagnosis

* $p<0.05$

Table 4: Adjusted hazard ratios (95% confidence intervals) of antidepressant use using multivariate Cox regression models

	Patients with depressed mood[±] (n=483)			Patients with depressed mood and agitation/psychosis[±] (n=170)			Patients with agitation/psychosis, but not depressed mood[±] (n=653)			Patients without neuropsychiatric symptoms[±] (n=3,975)		
	N prescribed antidepressant (%)	Model 1	Model 2	N prescribed antidepressant (%)	Model 1	Model 2	N prescribed antidepressant (%)	Model 1	Model 2	N prescribed antidepressant (%)	Model 1	Model 2
Antidepressant receipt prior (and post) dementia diagnosis	208 (43.1%)	**1.42 (1.03-1.97)***	**1.56 (1.12-2.17)***	85 (50.0%)	0.85 (0.51-1.43)	0.97 (0.54-1.74)	117 (17.9%)	1.24 (0.94-1.63)	1.27 (0.95-1.69)	461 (11.6%)	**1.28 (1.10-1.49)***	**1.20 (1.03-1.39)***
Antidepressant receipt post dementia diagnosis	65 (13.5%)	1.13 (0.70-1.82)	1.11 (0.68-1.83)	24 (14.1%)	1.28 (0.67-2.46)	*1.91 (0.89-4.11)[#]*	64 (9.8%)	1.25 (0.91-1.72)	1.31 (0.94-1.83)	185 (4.7%)	**1.30 (1.04-1.61)***	*1.22 (0.97-1.53)[#]*

Model 1 = adjusted for demographics (includes age, gender, ethnicity, marital status, deprivation score at dementia diagnosis) and cognitive scores

Model 2 = Fully adjusted (see Table 3)

[±] using HoNOS65+ mental health problem subscales (a score of 2 or more represents a problem)

* p<0.05

# p<0.10